Neuropathic Pain Clinical Trial
Official title:
The Relationship Between Motor Threshold and Effective Stimulation Threshold During Motor Cortex Stimulation
Motor cortex stimulation (MCS) is a form of brain stimulation for patients with neuropathic
pain not responsive to medication. An electrode is placed on the surface of the brain and
connected to a programmable battery in the chest.
The strength of stimulation can be individually adjusted by changing the voltage of
stimulation. A too high voltage will produce side effects (e.g. seizures) while a too low
voltage will not provide pain control. The aim of this study is to analyze the optimal
stimulation parameters in patients already implanted with a motor cortex stimulation who
have received good pain relief. The actual voltage may vary widely between patients but the
investigators feel that there may be an "ideal" voltage if it is measured as a percentage of
motor threshold (PMT). If motor threshold is the stimulation voltage that can evoke a muscle
contraction then a PMT = 80% would be a voltage that was eighty percent of that value.
Although the actual voltage may be widely different between patients, the percentage needed
may be very similar. The investigators therefore plan to measure the effect of different
percentages of PMT in patients already being treated with motor cortex stimulation.
Systematic analysis of the findings of this study might help the individual participant and
future patients to better programming and less side effects.
Motor cortex stimulation (MCS) is a form of brain stimulation for patients with medically
refractory neuropathic pain. The strength of stimulation can be individually adjusted by
changing the voltage of stimulation. Too high voltage will produce side effects (e.g.
seizures) while too low voltage will not provide pain control. The aim of this study is to
analyze the optimal stimulation parameters in patients already implanted with a motor cortex
stimulation who have received good pain relief. The actual voltage may vary widely between
patients (because of the individual variations in tissue resistance) but the investigators
feel that there may be an "ideal" voltage if it is measured as a percentage of motor
threshold (PMT).
If motor threshold is the voltage that can evoke a muscle contraction then a PMT = 80% would
be a voltage that was eighty percent of that value. Although the actual voltage may be
different between patients, the effective PMT may be similar since it represents a more
physiologic measure of stimulation.
Systematic analysis of the findings of this study might help the individual participant and
future patients by reducing voltage to the lowest effective setting and reducing the chance
of seizures.
Motor cortex stimulation is used in the treatment of neuropathic pain since 1991 but still
no guidelines for programming exist and programming is therefore mainly bases on trial and
error. This is mostly due to many variables influencing the choice of stimulation parameters
and significant individual differences in susceptibility to stimulation. Routinely the motor
threshold is determined during programming to identify the superior limit of voltage at
which twitching is induced. No stimulation above the motor threshold should be performed as
this is known to cause seizures. The voltage of simulation that will be effective for an
individual is unknown at the beginning of the treatment.
The investigators try to find the lowest effective voltage because that will reduce the risk
of stimulation-induced seizures and prolong the life of the pacemaker.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04699734 -
Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Completed |
NCT05235191 -
Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies
|
Phase 3 | |
Completed |
NCT05845177 -
Persistent Pain After Hip Replacement
|
||
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT05949554 -
Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
|
||
Withdrawn |
NCT05052645 -
Ear Acupuncture for Neuropathic Pain
|
N/A | |
Completed |
NCT02930551 -
Neuromas as the Cause of Pain
|
N/A | |
Completed |
NCT02866396 -
Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement
|
||
Completed |
NCT02824588 -
Working Memory Training for Chronic Neuropathic and Fibromyalgia Pain
|
N/A | |
Active, not recruiting |
NCT02560545 -
Cannabinoids Effects on the Pain Modulation System
|
N/A | |
Enrolling by invitation |
NCT02485795 -
Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management
|
N/A | |
Not yet recruiting |
NCT02246517 -
The Effect of N2O on Chronic Neuropathic Pain Patients
|
Phase 0 | |
Completed |
NCT02099890 -
The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT01946555 -
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
|
N/A | |
Completed |
NCT01718821 -
Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients
|
N/A | |
Completed |
NCT01884662 -
Virtual Walking for Neuropathic Pain in Spinal Cord Injury
|
N/A | |
Completed |
NCT01669967 -
The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin
|
N/A | |
Completed |
NCT01207596 -
Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain
|
Phase 4 | |
Completed |
NCT01201317 -
A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy
|
Phase 2 |